Kompass Diagnostics has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I grant for $305,000 to advance the development of a portable, cost-effective rapid point of care diagnostic device that utilizes high sensitivity biosensors for detecting multiple blood-based biomarkers. 

The field of reproductive endocrinology and infertility (REI) is at a crossroads. With a mismatch between demand for fertility treatments and a low accessibility of care due to shortage of workforce, geographic misdistribution of clinics, and low financial coverage. Kompass Diagnostics is developing a solution that can be used by clinicians and patients to obtain rapid hormone level results at the point of care and at home to enable convenient, cost-effective care delivery beyond hospital walls.

“We are honored to receive this SBIR Phase I grant from the National Science Foundation,” said Mingoo Kim, co-founder and CEO of Kompass Diagnostics. “This project will lay the foundation to expand into other point of care applications, including the rapid high-sensitivity detection of cardiac troponin and Alzheimer’s-related small proteins.”

America’s Seed Fund powered by NSF awards $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $2 million to support research and development (R&D), helping de-risk technology for commercial success. America’s Seed Fund is congressionally mandated through the Small Business Innovation Research (SBIR) program. The NSF is an independent federal agency with a budget of about $8.5 billion that supports fundamental research and education across all fields of science and engineering. 

Read more: https://nsf.elsevierpure.com/en/projects/sbir-phaseportable-blood-diagnostic-technology-enabling-care-deli